⌘K

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

Bleomycin-Induced Pulmonary Fibrosis | Accelerate Your Fibrosis Research

Home/Models/Bleomycin-Induced Pulmonary Fibrosis

Bleomycin-Induced Pulmonary Fibrosis

chemicalfibrosislung

Species

Mouse

Duration

Protocol ID

M-cG9zdDoyMjY=

Model Overview

Gold standard model for idiopathic pulmonary fibrosis (IPF) research.

Methodology

Key Endpoints

Ashcroft fibrosis score
Hydroxyproline content
Lung function

Relevant Publications

Bleomycin-induced lung fibrosis and dysfunction is exacerbated by G6PD deficiency.

Signoretti C, Fatehi S, Drewes R et al.

Am J Physiol Lung Cell Mol Physiol2025 Dec 16

Photodynamic therapy with a novel photosensitizer inhibits BLM-induced pulmonary fibrosis in mice via MRC1-mediated pathway.

Zhu M, Wang N, Zhang F et al.

Front Pharmacol2025

Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors for the Treatment of Pulmonary Fibrosis.

Zeng W, Hua X, Wang Z et al.

J Med Chem2025 Dec 15

Identification of key anti-pulmonary fibrosis components in Hyssopus cuspidatus Boriss. and its mechanism exploration.

Zhao YY, Weng ZB, Chen NY et al.

Phytomedicine2025 Dec 5

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis.

Ni B, Gong Y, Li B et al.

Front Microbiol2025

View more on PubMed

Related Drugs

GB0139

Phase 2b

gb0139

STM-434

Phase 2a

stm-434

PBI-4050

Phase 2b

pbi-4050

Bexotegrast

Phase 3

bexotegrast

Pamrevlumab

Phase 3

pamrevlumab

Nerandomilast

Approved

nerandomilast

Pirfenidone (Esbriet)

Approved

pirfenidone

Nintedanib (Ofev)

Approved

nintedanib